Heron Therapeutics, Inc. (HRTX) Earnings Call Transcripts
Heron Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Heron Therapeutics reported net revenues of $34.7 million, slightly below expectations due to seasonal headwinds and severe weather impacting elective surgeries. The company maintained its full-year guidance of $173 million to $183 million in net product sales and adjusted EBITDA of $10 million to $20 million. Management highlighted a strong recovery in March with net sales exceeding $15 million, indicating potential for improved performance in the upcoming quarters.
Reported metrics
| Metric | Value |
|---|---|
| Net Revenue | $34.7 million (miss) |
| Gross Margin | 69% (negative) |
| Adjusted EBITDA | -$727,000 (miss) |
| ZYNRELEF Revenue Growth | 27% (positive) |
| APONVIE Revenue Growth | over 50% (positive) |
| CINVANTI Market Share | 25% (inline) |
Guidance from management
Heron maintained its full-year guidance for net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, indicating confidence in recovery as elective procedures are rescheduled throughout the year.
What management said
Brandon, I appreciate those questions. I'll begin with the Baxter settlement, after which I'll hand things to Mark. Given what the settlement stipulates, we truly cannot elaborate on it beyond noting the dates and all other information already made public; apart from that, we are simply prohibited from commenting further on it; therefore I'll pass it to Mark so he can address the ZYNRELEF topics you raised.
What analysts pressed on
Analysts expressed concerns regarding the impact of severe weather on surgical volumes and how this might affect future sales. There were also questions about the effectiveness of the IGNITE program and how management plans to overcome adoption friction for ZYNRELEF and APONVIE.
Main topics on the call
- Revenue Performance — Heron reported total net sales of $34.7 million for Q1 2026, which reflects a decline attributed to seasonal factors and weather disruptions. CEO Craig Collard noted, "January was our most difficult month since I joined ...
- Acute Care Portfolio Growth — The Acute Care portfolio saw a revenue growth of 32% year-over-year, with ZYNRELEF growing 27% and APONVIE growing over 50%. Collard stated that the IGNITE program has been a key growth driver for ZYNRELEF, which is expe...
- Sales Force Expansion — Heron plans to expand its sales force in Q3 2026, which is viewed as a significant catalyst for growth. Management expressed confidence that this expansion will enhance market share for both ZYNRELEF and APONVIE.
- CINVANTI Market Stability — CINVANTI maintained a stable market share of 25% in the NK1 category despite competitive pressures. Management highlighted that the product's performance has remained resilient, with a consistent customer base and new ac...
Read the full Heron Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (HRTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 19 calls on record spanning November 3, 2021 to August 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 19 Heron Therapeutics, Inc. earnings call transcripts on record, spanning November 3, 2021 to August 10, 2026. Based on this history, Heron Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the transcript.
- Ticker
- HRTX
- Exchange
- NASDAQ
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 19
- First call
- November 3, 2021
- Most recent
- August 10, 2026
- Reporting cadence
- quarterly
| Quarter | Date | |
|---|---|---|
| Q2 FY2026 | Aug 10, 2026 | Read transcript → |
| Q1 FY2026 | May 11, 2026 | Read transcript → |
| Q4 FY2025 | Feb 26, 2026 | Read transcript → |
| Q3 FY2025 | Nov 4, 2025 | Read transcript → |
| Q2 FY2025 | Aug 8, 2025 | Read transcript → |
| Q4 FY2024 | Feb 27, 2025 | Read transcript → |
| Q3 FY2024 | Nov 12, 2024 | Read transcript → |
| Q2 FY2024 | Aug 6, 2024 | Read transcript → |
| Q1 FY2024 | May 7, 2024 | Read transcript → |
| Q4 FY2023 | Mar 12, 2024 | Read transcript → |
| Q3 FY2023 | Nov 14, 2023 | Read transcript → |
| Q2 FY2023 | Aug 14, 2023 | Read transcript → |
| Q1 FY2023 | May 11, 2023 | Read transcript → |
| Q4 FY2022 | Mar 23, 2023 | Read transcript → |
| Q3 FY2022 | Nov 8, 2022 | Read transcript → |
| Q2 FY2022 | Aug 9, 2022 | Read transcript → |
| Q1 FY2022 | May 9, 2022 | Read transcript → |
| Q4 FY2021 | Feb 28, 2022 | Read transcript → |
| Q3 FY2021 | Nov 3, 2021 | Read transcript → |